Trump’s pharma tariffs put Singapore at ‘greatest risk’ among major exporters if no exemptions granted: economists
Without exemptions, the effective tariff rate on the Republic’s shipments could exceed 30%, compared with 4% now
Add BT as a preferred source
[SINGAPORE] The Trump administration’s latest tariff salvo – this time aimed at branded or patented pharmaceutical goods – could hit Singapore particularly hard, economists warned.
On Thursday (Sep 25), Trump announced a 100 per cent tariff on imports of branded or patented pharmaceutical goods from Oct 1, unless a company has already begun construction of a plant in the United States.
Pharmaceutical firms that have broken ground on US facilities will receive exemptions, Trump said.
TRENDING NOW
Why China is tightening controls on overseas stock trading
Xi Jinping has just rewritten the rules of US-China rivalry
‘Even a CEO’s job can be replaced by AI’: DBS CEO Tan Su Shan bets big on agentic AI
‘Whole deck of cards just toppled’: FoodXervices’ Nichol Ng on how a 92-year-old family business unravelled – and what’s next
